Format

Send to

Choose Destination
J Clin Invest. 2019 Sep 30. pii: 128699. doi: 10.1172/JCI128699. [Epub ahead of print]

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.

Author information

1
Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA.
2
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
3
Division of AIDS, NIH, Bethesda, Maryland, USA.
4
Columbia University Medical Center, New York, New York, USA.
5
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
6
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
7
New York Blood Center, New York, New York, USA.
8
University of Washington, Seattle, Washington, USA.
9
UCSF, San Francisco, California, USA.
10
Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA.
11
Global Solutions for Infectious Diseases, South San Francisco, California, USA.
12
Division of Immunology and Allergy, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
13
EuroVacc Foundation, Lausanne, Switzerland.
14
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

Abstract

BACKGROUNDRV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODSOne hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTSAll regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final vaccination at high magnitude. While IgG3 responses were highest in T3, a lower IgA/IgG ratio was observed in T4. Binding antibodies persisted at 12 months in 35%-100% of participants. Antibody-dependent cell-mediated cytotoxicity and tier 1 neutralizing-antibody responses had higher response rates for T3 and T4, respectively. CD4+ T cell responses were detectable in all treatment groups (32%-64%) without appreciable CD8+ T cell responses.CONCLUSIONThe DNA/protein combination regimens induced high-magnitude and long-lasting HIV V1V2-binding antibody responses, and early coadministration of the 2 vaccines led to a more rapid induction of these potentially protective responses.TRIAL REGISTRATIONClinicalTrials.gov NCT02207920.FUNDINGNational Institute of Allergy and Infectious Diseases (NIAID) grants UM1 AI068614, UM1 AI068635, UM1 AI068618, UM1 AI069511, UM1 AI069470, UM1 AI069534, P30 AI450008, UM1 AI069439, UM1 AI069481, and UM1 AI069496; the National Center for Advancing Translational Sciences, NIH (grant UL1TR001873); and the Bill & Melinda Gates Foundation (grant OPP52845).

KEYWORDS:

AIDS vaccine; AIDS/HIV; Vaccines

PMID:
31566579
DOI:
10.1172/JCI128699
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center